Drug Insight: aspirin resistance—fact or fashion?

Patrono C et al. (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373–2383

Born G and Patrono C (2006) Antiplatelet drugs. Brit J Pharmacol 147 (Suppl 1): S241–S251

Patrignani P et al. (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366–1372

FitzGerald GA et al. (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 678–688

Helgason CM et al. (1993) Aspirin response and failure in cerebral infarction. Stroke 24: 1259–1261

Helgason CM et al. (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25: 2331–2336

Hankey GJ and Eikelboom JW (2006) Aspirin resistance. Lancet 367: 606–617

Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1: 1710–1713

Glossary of Department of Health and Human Services Center for Disease Control and Prevention [ http://www.cdc.gov/drugresistance/glossary.htm ]

Rocca B et al. (2002) Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 99: 7634–7639

Halushka MK et al. (2003) Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73: 122–130

Maree AO et al. (2005) Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3: 2340–2345

Wang TH et al. (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647–654

Patrono C et al. (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl 3): S234–S264

FitzGerald GA et al. (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174–1177

Patrono C et al. (1980) Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17: 317–327

Patrono C et al. (1986) Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77: 590–594

Reilly IA and FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69: 180–186

Yu Y et al. (2005) Differential impact of prostaglandin H synthase 1 knock-down on platelets and parturition. J Clin Invest 115: 986–995

Fontana P et al. (2005) Aspirin and clopidogrel resistance: a study on 96 healthy volunteers and role of the P2Y12 H1/H2 gene polymorphism [abstract # P0356]. J Thromb Haemost 3 (Suppl 1)

Maree AO et al. (2005) Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46: 1258–1263

Capone ML et al. (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109: 1468–1471

Capone ML et al. (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45: 1295–1301

Tantry US et al. (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46: 1705–1709

Cipollone F et al. (2004) Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24: 246–255

Evangelista V et al. (2006) De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 98: 593–595

Vejar M et al. (1990) Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost 63: 163–168

Cipollone F et al. (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in unstable angina. Circulation 96: 1109–1116

Cipollone F et al. (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102: 1007–1013

Van Kooten F et al. (1999) Increased thromboxane biosynthesis is associated with post-stroke dementia. Stroke 30: 1542–1547

Eikelboom JW et al. (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655

Hennekens CH et al. (2004) Terms and conditions: semantic complexity and aspirin resistance. Circulation 110: 1706–1708

Harrison P et al. (2005) Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36: 1001–1005

Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980–1987

Patrono C et al. (2004) Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 25: 166–181

Michelson AD et al. (2005) Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3: 1309–1311

Pedersen AK and FitzGerald GA (1984) Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311: 1206–1211

Loll PJ et al. (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2: 637–643

Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817

Corman SL et al. (2005) Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin. Ann Pharmacother 39: 1073–1079

García Rodríguez LA et al. (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000–3006

Roth GJ et al. (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72: 3073–3076

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360

Landolfi R et al. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114–124

Gum PA et al. (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41: 961–965

Matetzky S et al. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patiens with acute myocardial infarction. Circulation 109: 3171–3175